EA201890068A1 - Частицы диметилфумарата и фармацевтические композиции на их основе - Google Patents
Частицы диметилфумарата и фармацевтические композиции на их основеInfo
- Publication number
- EA201890068A1 EA201890068A1 EA201890068A EA201890068A EA201890068A1 EA 201890068 A1 EA201890068 A1 EA 201890068A1 EA 201890068 A EA201890068 A EA 201890068A EA 201890068 A EA201890068 A EA 201890068A EA 201890068 A1 EA201890068 A1 EA 201890068A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- particles
- dimethylate
- basis
- dmf
- pharmaceutical compositions
- Prior art date
Links
- 239000002245 particle Substances 0.000 title abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- LDCRTTXIJACKKU-ONEGZZNKSA-N dimethyl fumarate Chemical compound COC(=O)\C=C\C(=O)OC LDCRTTXIJACKKU-ONEGZZNKSA-N 0.000 abstract 5
- 229960004419 dimethyl fumarate Drugs 0.000 abstract 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 239000002552 dosage form Substances 0.000 abstract 1
- 201000006417 multiple sclerosis Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/225—Polycarboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Emergency Medicine (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562181061P | 2015-06-17 | 2015-06-17 | |
| PCT/US2016/037486 WO2016205270A1 (en) | 2015-06-17 | 2016-06-15 | Dimethyl fumarate particles and pharmaceutical compositions thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| EA201890068A1 true EA201890068A1 (ru) | 2018-09-28 |
Family
ID=56292916
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EA201890068A EA201890068A1 (ru) | 2015-06-17 | 2016-06-15 | Частицы диметилфумарата и фармацевтические композиции на их основе |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11291642B2 (https=) |
| EP (1) | EP3310341A1 (https=) |
| JP (2) | JP2018517735A (https=) |
| KR (1) | KR20180018711A (https=) |
| CN (1) | CN107920997A (https=) |
| AU (2) | AU2016279997B2 (https=) |
| CA (1) | CA2989581A1 (https=) |
| EA (1) | EA201890068A1 (https=) |
| HK (1) | HK1254054A1 (https=) |
| IL (1) | IL256296A (https=) |
| MA (1) | MA42196A (https=) |
| MX (1) | MX387092B (https=) |
| WO (1) | WO2016205270A1 (https=) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016344673A1 (en) * | 2015-10-28 | 2018-05-17 | Sun Pharmaceutical Industries Limited | Pharmaceutical compositions of dimethyl fumarate |
| JP6902043B2 (ja) * | 2016-02-11 | 2021-07-14 | バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． | フマル酸ジメチルを含む医薬ビーズ製剤 |
| CA3075720A1 (en) * | 2017-10-02 | 2019-04-11 | Novartis Ag | Method for preparing a pharmaceutical product |
| WO2019194826A1 (en) | 2018-04-06 | 2019-10-10 | Hewlett-Packard Development Company, L.P. | Three-dimensional (3d) object printing based on build material permeability |
| CA3115516C (en) * | 2018-10-05 | 2023-04-25 | Isp Investments Llc | Smooth high solids film coating composition comprising water soluble cellulose ether, process for preparing the same and method of use thereof |
| TR201818293A2 (tr) * | 2018-11-30 | 2020-06-22 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Di̇meti̇l fumarat i̇çeren geci̇kmeli̇ salim sağlayan kapsül |
| EP3917500A2 (en) * | 2019-01-31 | 2021-12-08 | Elektrofi, Inc. | Particle formation and morphology |
| JP2022525482A (ja) * | 2019-03-20 | 2022-05-16 | リンドラ セラピューティクス， インコーポレイティド | 胃内滞留剤形用のコーティング |
| MX2021011314A (es) * | 2019-03-20 | 2021-12-10 | Lyndra Therapeutics Inc | Capsulas y recubrimientos de capsulas para formas de dosificacion de residencia gastrica. |
| JP2023553274A (ja) * | 2020-11-18 | 2023-12-21 | エフビー－エイチアールエス リミテッド ライアビリティ カンパニー | ドフェチリド及びメキシレチンを含有する組成物並びにその使用 |
| CN116887866A (zh) | 2020-12-03 | 2023-10-13 | 巴特尔纪念研究院 | 聚合物纳米颗粒和dna纳米结构组合物及用于非病毒递送的方法 |
| WO2022216977A1 (en) | 2021-04-07 | 2022-10-13 | Batelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| AU2022285951A1 (en) | 2021-06-04 | 2024-01-04 | Zim Laboratories Limited | Delayed release compositions of dimethyl fumarate |
| US11590071B2 (en) * | 2021-07-06 | 2023-02-28 | King Abdulaziz University | Injectable drug delivery implant composition and method of use thereof |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| WO2025090498A1 (en) * | 2023-10-23 | 2025-05-01 | Isp Investments Llc | Encapsulated medium chain fatty acid salts and oral solid dosage forms derived therefrom |
| US12441996B2 (en) | 2023-12-08 | 2025-10-14 | Battelle Memorial Institute | Use of DNA origami nanostructures for molecular information based data storage systems |
| US12303604B1 (en) | 2024-10-16 | 2025-05-20 | Currax Pharmaceuticals Llc | Pharmaceutical formulations comprising naltrexone and/or bupropion |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2725623A1 (fr) | 1994-10-18 | 1996-04-19 | Flamel Tech Sa | Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os |
| US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
| DE19853487A1 (de) | 1998-11-19 | 2000-05-25 | Fumapharm Ag Muri | Verwendung von Dialkylfumaraten |
| IL133196A0 (en) | 1999-11-29 | 2001-03-19 | Yissum Res Dev Co | Gastroretentive controlled release pharmaceutical dosage forms |
| DE10101307A1 (de) | 2001-01-12 | 2002-08-01 | Fumapharm Ag Muri | Fumarsäurederivate als NF-kappaB-Inhibitor |
| US8101209B2 (en) | 2001-10-09 | 2012-01-24 | Flamel Technologies | Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles |
| US6723340B2 (en) | 2001-10-25 | 2004-04-20 | Depomed, Inc. | Optimal polymer mixtures for gastric retentive tablets |
| LT2801354T (lt) * | 2004-10-08 | 2017-06-26 | Forward Pharma A/S | Kontroliuojamo atpalaidavimo farmacinės kompozicijos, apimančios fumaro rūgšties esterį |
| HUE043365T2 (hu) | 2006-01-18 | 2019-08-28 | Intec Pharma Ltd | Kiadóberendezés szer orális bevételéhez |
| KR101601649B1 (ko) * | 2008-04-18 | 2016-03-09 | 인텍 파마 리미티드 | 카르비도파／레보도파 위체류 약물 전달 |
| JP2012514623A (ja) * | 2009-01-09 | 2012-06-28 | フォーワード・ファルマ・アクティーゼルスカブ | １またはそれ以上のフマル酸エステルを含む医薬組成物 |
| WO2010079222A1 (en) * | 2009-01-09 | 2010-07-15 | Forward Pharma A/S | Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix |
| SMT201800098T1 (it) * | 2011-06-08 | 2018-03-08 | Biogen Ma Inc | Processo per la preparazione di dimetilfumarato cristallino e con purezza elevata |
| RU2014125430A (ru) * | 2011-11-24 | 2015-12-27 | Синтон Бв | Контролируемое высвобождение частиц, содержащих диметилфумарат |
| NZ627980A (en) * | 2012-02-07 | 2016-12-23 | Biogen Ma Inc | Pharmaceutical compositions containing dimethyl fumarate |
| US20150079180A1 (en) * | 2013-09-18 | 2015-03-19 | Xenoport, Inc. | Nanoparticle compositions of dimethyl fumarate |
| IN2013MU03070A (https=) * | 2013-09-25 | 2015-07-17 | Glenmark Pharmaceuticals Ltd | |
| EP3079663A1 (en) * | 2013-12-13 | 2016-10-19 | Biogen MA Inc. | Controlled release dosage form for once daily administration of dimethyl fumarate |
| AU2015222880B2 (en) | 2014-02-28 | 2016-11-24 | Banner Life Sciences Llc | Controlled release enteric soft capsules of fumarate esters |
-
2016
- 2016-06-15 MX MX2017016509A patent/MX387092B/es unknown
- 2016-06-15 EP EP16733793.0A patent/EP3310341A1/en not_active Withdrawn
- 2016-06-15 US US15/737,011 patent/US11291642B2/en active Active
- 2016-06-15 HK HK18113117.1A patent/HK1254054A1/zh unknown
- 2016-06-15 WO PCT/US2016/037486 patent/WO2016205270A1/en not_active Ceased
- 2016-06-15 AU AU2016279997A patent/AU2016279997B2/en not_active Ceased
- 2016-06-15 EA EA201890068A patent/EA201890068A1/ru unknown
- 2016-06-15 CN CN201680047251.2A patent/CN107920997A/zh active Pending
- 2016-06-15 JP JP2017565133A patent/JP2018517735A/ja active Pending
- 2016-06-15 MA MA042196A patent/MA42196A/fr unknown
- 2016-06-15 CA CA2989581A patent/CA2989581A1/en active Pending
- 2016-06-15 KR KR1020187001091A patent/KR20180018711A/ko not_active Ceased
-
2017
- 2017-12-13 IL IL256296A patent/IL256296A/en unknown
-
2021
- 2021-11-12 JP JP2021184469A patent/JP2022042512A/ja active Pending
-
2022
- 2022-01-12 AU AU2022200155A patent/AU2022200155A1/en not_active Abandoned
- 2022-02-22 US US17/677,204 patent/US20220362195A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| WO2016205270A1 (en) | 2016-12-22 |
| JP2018517735A (ja) | 2018-07-05 |
| CA2989581A1 (en) | 2016-12-22 |
| MA42196A (fr) | 2018-04-25 |
| AU2016279997B2 (en) | 2021-10-21 |
| WO2016205270A8 (en) | 2017-01-19 |
| HK1254054A1 (zh) | 2019-07-12 |
| US20220362195A1 (en) | 2022-11-17 |
| MX387092B (es) | 2025-03-19 |
| CN107920997A (zh) | 2018-04-17 |
| KR20180018711A (ko) | 2018-02-21 |
| AU2016279997A1 (en) | 2018-01-18 |
| US11291642B2 (en) | 2022-04-05 |
| AU2022200155A1 (en) | 2022-02-10 |
| US20190070143A1 (en) | 2019-03-07 |
| MX2017016509A (es) | 2018-08-16 |
| EP3310341A1 (en) | 2018-04-25 |
| IL256296A (en) | 2018-02-28 |
| JP2022042512A (ja) | 2022-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201890068A1 (ru) | Частицы диметилфумарата и фармацевтические композиции на их основе | |
| CL2020001852A1 (es) | Procesos de preparación de s-ketamina o clorhidrato de s-ketamina o productos derivados de éste. (divisional solicitud 201901066) | |
| CY1121359T1 (el) | Ενωσεις ετεροαρυλιου για αναστολη κινασης | |
| PH12019500095A1 (en) | Compounds, compositions, and methods for the treatment of disease | |
| EA201991862A1 (ru) | Композиции и способы, предназначенные для лечения гемоглобинопатий | |
| MX2018009325A (es) | Compuestos y metodos para tratar enfermedades mediadas por el acido ribonucleico (arn). | |
| EA201890325A1 (ru) | Пептидные ингибиторы рецептора интерлейкина-23 и их применение для лечения воспалительных заболеваний | |
| MX2022013524A (es) | Anticuerpos neutralizantes para el virus de inmunodeficiencia humana. | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| EA201791874A1 (ru) | Фторированные ингибиторы лизилоксидазоподобного фермента-2 и их применение | |
| TW201613859A (en) | Analogs of PRIDOPIDINE, their preparation and use | |
| EA201692201A1 (ru) | Соединения и композиции в качестве агонистов toll-подобного рецептора 7 | |
| MX395317B (es) | Anticuerpos de grupo de diferenciacion 3 (cd3) humanizados o quimericos. | |
| WO2016100619A3 (en) | Treatment and diagnosis of cancer | |
| CY1125150T1 (el) | Ενωσεις φαινυλο-2-υδροξυ-ακετυλαμινο-2-μεθυλο-φαινυλιου | |
| EA201791096A1 (ru) | 4-оксо-3,4-дигидро-1,2,3-бензотриазины в качестве модуляторов gpr139 | |
| EA201990400A1 (ru) | Соединения и композиции и их применение | |
| EP3802539C0 (en) | NOVEL TETRAHYDRO-1H-PYRAZINO[2,1-A]ISOINDOLYLQUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASES | |
| EP3630102C0 (en) | FORMULATIONS FOR THE TREATMENT OF POST-TRAUMATIC STRESS DISORDER | |
| JOP20190190A1 (ar) | معالجة سرطان | |
| AU2016380190A8 (en) | Deuterated compounds for treating cancer and related diseases and conditions, and compositions and methods thereof | |
| MX381224B (es) | Potentes moduladores de gamma-secretasa. | |
| CL2016001763A1 (es) | Antagonistas selectivos de nr2b | |
| EP3638283C0 (en) | CALCIUM CHANNEL ANTAGONISTS OF THE CAV2.3 R TYPE FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | |
| MX378739B (es) | Compuestos de 2-oxindol. |